Skriftligt spörsmål om ersättning för antikoagulationsmedel vid behandling av svåra infektioner orsakade av coronaviruset

This written question seeks clarification on the reimbursement of anticoagulants used to treat severe infections and blood clots caused by the coronavirus. It addresses whether current medicine reimbursement systems adequately cover these treatments for patients suffering from these specific complications. The procedure affects patients requiring anticoagulation therapy for COVID-19 and the healthcare providers managing medicine reimbursement and disease classifications.